FDA approves first treatment, Soliris, for neuromyelitis optica spectrum disorder

FDA approves first treatment, Soliris, for neuromyelitis optica spectrum disorder

Silver Spring, MD (STL.News) – The U.S. Food and Drug Administration yesterday approved Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.  NMOSD is an autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord.

“Soliris provides the first FDA-approved treatment for neuromyelitis optica spectrum disorder, a debilitating disease that profoundly impacts patients’ lives,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. 

Continue reading FDA approves first treatment, Soliris, for neuromyelitis optica spectrum disorder at STL.News.